title: Report of AIDS-related lymphoma in South Korea.
abstract: BACKGROUND
  The prevalence of AIDS-related lymphoma (ARL) is increasing in South Korea. The aim of this study is to identify the clinical features of ARL in South Korea.
  
  
  METHODS
  From 1998 through 2006, we retrospectively analysed a total of 23 cases of ARL from seven institutions.
  
  
  RESULTS
  The patients consisted of 20 males and 3 females at a median age of 40 (range, 20-72) on diagnosis of AIDS. ARL developed at their median age of 41 (range, 24-72). The histological diagnosis was aggressive B cell lymphoma in the majority, but rare T cell and NK/T cell lymphoma were also included. Ten of 23 (43.5%) was receiving highly active anti-retroviral therapy (HAART) before the diagnosis of ARL. Fifteen of twenty-three patients were given combination chemotherapy with/without radiation, four were given radiation alone, and four did not receive any treatment against medical advice. Of 20 patients followed-up, nine were alive in remission, two alive in disease, one died of treatment related complication, four died of progressive lymphoma, four died of AIDS related causes. The response to treatment included CR in eight (44.4%), PR in four (22.2%) and PD in three (16.7%). The response to HARRT was evaluable in 13 patients based on CD4+ cell count and HIV viral load, among which nine (69.2%) responded. Estimated median survival time was 43.9 months.
  
  
  CONCLUSIONS
  Although the population of patients is small, this is the first clinical data analyses of Korean ARL patients. As a substantial portion of the patients remains alive disease free, the impact of HAART on the clinical course of ARL needs further follow-up and evaluation.
authors.affiliation: Department of Medicine, Inha University Hospital, 7-206, 3rd street, Shinheung-dong, Jung-gu, Incheon 400-711, South Korea. cskimmd@inha.ac.kr.
authors.forename: Jin-Soo
authors.initials: JS
authors.lastname: Kim
authors.forename: Seok Jin
authors.initials: SJ
authors.lastname: Kim
authors.forename: Jin-Seok
authors.initials: JS
authors.lastname: Kim
authors.forename: Eun Sun
authors.initials: ES
authors.lastname: Kim
authors.forename: Ho-Jin
authors.initials: HJ
authors.lastname: Shin
authors.forename: Joo Seop
authors.initials: JS
authors.lastname: Chung
authors.forename: Yoo-Hong
authors.initials: YH
authors.lastname: Min
authors.forename: Moon Hee
authors.initials: MH
authors.lastname: Lee
authors.forename: Young Jin
authors.initials: YJ
authors.lastname: Choi
authors.forename: Soo-Mee
authors.initials: SM
authors.lastname: Bang
authors.forename: Jung A
authors.initials: JA
authors.lastname: Kim
authors.forename: Goon Jae
authors.initials: GJ
authors.lastname: Cho
authors.forename: Hyun-Sook
authors.initials: HS
authors.lastname: Chi
authors.forename: Seong Soo
authors.initials: SS
authors.lastname: Jang
authors.forename: Chan Jeoung
authors.initials: CJ
authors.lastname: Park
authors.forename: Cheolwon
authors.initials: C
authors.lastname: Suh
authors.forename: Chong Won
authors.initials: CW
authors.lastname: Park
authors.forename: Chul Soo
authors.initials: CS
authors.lastname: Kim
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D007723:Korea / Q000453:epidemiology; D016483:Lymphoma, AIDS-Related / Q000188:drug therapy / Q000453:epidemiology* / Q000532:radiotherapy / Q000628:therapy*; D016393:Lymphoma, B-Cell / Q000453:epidemiology / Q000628:therapy; D016399:Lymphoma, T-Cell / Q000453:epidemiology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome